STVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Stevanato Group SpA (STVN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown solid financial growth in Q3 2025, the lack of significant positive trading signals, neutral insider and hedge fund activity, and the absence of strong upward momentum in technical indicators suggest that waiting for a clearer entry point may be prudent. Analysts have also lowered price targets recently, indicating potential headwinds in the injectable packaging market.
The MACD is positive but contracting, RSI is neutral at 33.413, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 15.094) in pre-market at $15.31, but there is no strong bullish signal.
The company has demonstrated strong financial growth in Q3 2025, with revenue up 9.11% YoY, net income up 20.11% YoY, and EPS up 18.18% YoY. Analysts believe the risk from oral GLP-1 drugs is limited in the near term, which could support the injectable packaging market.
Jefferies recently lowered the price target from $23 to $17.50, citing headwinds in the injectable packaging market. Technical indicators show no clear upward momentum, and the stock has a 70% chance of declining slightly in the next week and month.
In Q3 2025, Stevanato Group reported revenue of $303.17M (up 9.11% YoY), net income of $36.06M (up 20.11% YoY), EPS of $0.13 (up 18.18% YoY), and gross margin of 29.82% (up 6.31% YoY).
Jefferies has downgraded the price target to $17.50 from $23, maintaining a Hold rating. Analysts believe oral GLP-1 drugs will have limited market penetration in the near term, but headwinds in the injectable packaging market remain a concern.
